BRNS

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company based in Harwell, United Kingdom, dedicated to pioneering T cell immunotherapeutics that strengthen the immune response against chronic infectious diseases, autoimmune disorders, and various cancers. With a strong emphasis on innovative research and development, Barinthus seeks to transform the treatment landscape through targeted immunotherapies that address pressing health challenges. As it advances its portfolio of therapies, the company positions itself as a key player in the evolution of next-generation immunological treatments, potentially significantly impacting patient outcomes.